P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen
Identifieur interne : 000651 ( Main/Exploration ); précédent : 000650; suivant : 000652P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen
Auteurs : M C Schreiner [Autriche] ; G. Stingl [Autriche] ; A. Rieger [Autriche] ; A. Jalili [Autriche]Source :
- Sexually Transmitted Infections [ 1368-4973 ] ; 2013-07.
Descripteurs français
English descriptors
- KwdEn :
- Cohort, Disclosure, Disclosure sessions, Female students, Focus group discussions, Gender, Health services, High risk, Incidence rate, Informant interviews, Kumasi, Lbti, Lbti women, Medical university, Needlestick injuries, Neuropsychological, Paediatric disclosure, Pregnancy rates, Qualitative study, Sexual experiences, Stigma, Transactional, Truck drivers, Zambia, Zimbabwe.
- Teeft :
- Cohort, Disclosure, Disclosure sessions, Female students, Focus group discussions, Gender, Health services, High risk, Incidence rate, Informant interviews, Kumasi, Lbti, Lbti women, Medical university, Needlestick injuries, Neuropsychological, Paediatric disclosure, Pregnancy rates, Qualitative study, Sexual experiences, Stigma, Transactional, Truck drivers, Zambia, Zimbabwe.
Abstract
Introduction PEP to HIV is a course of antiretroviral drugs administered within 72 hrs after events with high risk of exposure to HIV aiming to reduce the odds of established infection. We evaluated the putative HIV exposed individuals referred to the Medical university of Vienna general hospital and indicated for PEP in years 2008–2012. Methodology and Results We have analysed the data from 450 individuals. Our data demonstrates that: 44.1% are females, indication type: unprotected homosexual contact [28.5%, from which 45% of source patients (SPs) were HIV positive], needlestick injuries (22.8%, 37.5% HIV positive SPs), unprotected heterosexual contact (21.4%, 20% HIV positive SPs), occupational exposure (12.8%, 100% HIV positive SPs), rape (11.4%) and needle exchange by IVDUs (2.8%) where HIV status of SPs were unknown, PEP regimens were combination of lopinavir/ritonavir with tenofovir/emtricitabine (79.4%), darunavir/ritonavir with tenofovir/emtricitabine (10.1%) or lopinavir/ritonavir with lamivudine/zidovudine (10.5%), 58.8% of individuals tolerated the PEP without any adverse events, 35.3% had minor adverse events (nausea, fatigue, diarrhoea, abdominal discomfort or slight elevation of pancreatic enzymes) and in 5.8% PEP was modified or discontinued (severe adverse events: strong diarrhoea, abdominal pain and vomiting or significant elevation of liver function parameters), 77.1% of patients missed at least one of their follow-up visits planned at 1, 3 and 6 months after PEP start, and no case of seroconversion was observed. Conclusion Approximately equal numbers of sexes seek counselling service for PEP. Most prevalent types of exposure include high risk sexual contact and needlestick injuries. Lopinavir/ritonavir with tenofovir/emtricitabine combination seems to be a well tolerated and effective therapy.
Url:
DOI: 10.1136/sextrans-2013-051184.0947
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000305
- to stream Istex, to step Curation: 000305
- to stream Istex, to step Checkpoint: 000016
- to stream Main, to step Merge: 000652
- to stream Main, to step Curation: 000651
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen</title><author><name sortKey="Schreiner, M C" sort="Schreiner, M C" uniqKey="Schreiner M" first="M C" last="Schreiner">M C Schreiner</name></author><author><name sortKey="Stingl, G" sort="Stingl, G" uniqKey="Stingl G" first="G" last="Stingl">G. Stingl</name></author><author><name sortKey="Rieger, A" sort="Rieger, A" uniqKey="Rieger A" first="A" last="Rieger">A. Rieger</name></author><author><name sortKey="Jalili, A" sort="Jalili, A" uniqKey="Jalili A" first="A" last="Jalili">A. Jalili</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6B45A1E5BBC905C5EEFC70C2A1B9A59154C18108</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/sextrans-2013-051184.0947</idno><idno type="url">https://api.istex.fr/document/6B45A1E5BBC905C5EEFC70C2A1B9A59154C18108/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000305</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000305</idno><idno type="wicri:Area/Istex/Curation">000305</idno><idno type="wicri:Area/Istex/Checkpoint">000016</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000016</idno><idno type="wicri:doubleKey">1368-4973:2013:Schreiner M:p:lopinavir:ritonavir</idno><idno type="wicri:Area/Main/Merge">000652</idno><idno type="wicri:Area/Main/Curation">000651</idno><idno type="wicri:Area/Main/Exploration">000651</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen</title><author><name sortKey="Schreiner, M C" sort="Schreiner, M C" uniqKey="Schreiner M" first="M C" last="Schreiner">M C Schreiner</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>DIAID, Department of Dermatology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Stingl, G" sort="Stingl, G" uniqKey="Stingl G" first="G" last="Stingl">G. Stingl</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>DIAID, Department of Dermatology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Rieger, A" sort="Rieger, A" uniqKey="Rieger A" first="A" last="Rieger">A. Rieger</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>DIAID, Department of Dermatology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Jalili, A" sort="Jalili, A" uniqKey="Jalili A" first="A" last="Jalili">A. Jalili</name><affiliation wicri:level="3"><country xml:lang="fr">Autriche</country><wicri:regionArea>DIAID, Department of Dermatology, Medical University of Vienna, Allgemeines Krankenhaus, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Sexually Transmitted Infections</title><title level="j" type="abbrev">Sex Transm Infect</title><idno type="ISSN">1368-4973</idno><idno type="eISSN">1472-3263</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2013-07">2013-07</date><biblScope unit="volume">89</biblScope><biblScope unit="issue">Suppl 1</biblScope><biblScope unit="page" from="A303">A303</biblScope></imprint><idno type="ISSN">1368-4973</idno></series><idno type="istex">6B45A1E5BBC905C5EEFC70C2A1B9A59154C18108</idno><idno type="DOI">10.1136/sextrans-2013-051184.0947</idno><idno type="href">sextrans-89-A303-3.pdf</idno><idno type="ArticleID">sextrans-2013-051184.0947</idno><idno type="local">sextrans;89/Suppl_1/A303-c</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1368-4973</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort</term><term>Disclosure</term><term>Disclosure sessions</term><term>Female students</term><term>Focus group discussions</term><term>Gender</term><term>Health services</term><term>High risk</term><term>Incidence rate</term><term>Informant interviews</term><term>Kumasi</term><term>Lbti</term><term>Lbti women</term><term>Medical university</term><term>Needlestick injuries</term><term>Neuropsychological</term><term>Paediatric disclosure</term><term>Pregnancy rates</term><term>Qualitative study</term><term>Sexual experiences</term><term>Stigma</term><term>Transactional</term><term>Truck drivers</term><term>Zambia</term><term>Zimbabwe</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Cohort</term><term>Disclosure</term><term>Disclosure sessions</term><term>Female students</term><term>Focus group discussions</term><term>Gender</term><term>Health services</term><term>High risk</term><term>Incidence rate</term><term>Informant interviews</term><term>Kumasi</term><term>Lbti</term><term>Lbti women</term><term>Medical university</term><term>Needlestick injuries</term><term>Neuropsychological</term><term>Paediatric disclosure</term><term>Pregnancy rates</term><term>Qualitative study</term><term>Sexual experiences</term><term>Stigma</term><term>Transactional</term><term>Truck drivers</term><term>Zambia</term><term>Zimbabwe</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Zambie</term><term>Zimbabwe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Introduction PEP to HIV is a course of antiretroviral drugs administered within 72 hrs after events with high risk of exposure to HIV aiming to reduce the odds of established infection. We evaluated the putative HIV exposed individuals referred to the Medical university of Vienna general hospital and indicated for PEP in years 2008–2012. Methodology and Results We have analysed the data from 450 individuals. Our data demonstrates that: 44.1% are females, indication type: unprotected homosexual contact [28.5%, from which 45% of source patients (SPs) were HIV positive], needlestick injuries (22.8%, 37.5% HIV positive SPs), unprotected heterosexual contact (21.4%, 20% HIV positive SPs), occupational exposure (12.8%, 100% HIV positive SPs), rape (11.4%) and needle exchange by IVDUs (2.8%) where HIV status of SPs were unknown, PEP regimens were combination of lopinavir/ritonavir with tenofovir/emtricitabine (79.4%), darunavir/ritonavir with tenofovir/emtricitabine (10.1%) or lopinavir/ritonavir with lamivudine/zidovudine (10.5%), 58.8% of individuals tolerated the PEP without any adverse events, 35.3% had minor adverse events (nausea, fatigue, diarrhoea, abdominal discomfort or slight elevation of pancreatic enzymes) and in 5.8% PEP was modified or discontinued (severe adverse events: strong diarrhoea, abdominal pain and vomiting or significant elevation of liver function parameters), 77.1% of patients missed at least one of their follow-up visits planned at 1, 3 and 6 months after PEP start, and no case of seroconversion was observed. Conclusion Approximately equal numbers of sexes seek counselling service for PEP. Most prevalent types of exposure include high risk sexual contact and needlestick injuries. Lopinavir/ritonavir with tenofovir/emtricitabine combination seems to be a well tolerated and effective therapy.</div></front></TEI><affiliations><list><country><li>Autriche</li></country><region><li>Vienne (Autriche)</li></region><settlement><li>Vienne (Autriche)</li></settlement></list><tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Schreiner, M C" sort="Schreiner, M C" uniqKey="Schreiner M" first="M C" last="Schreiner">M C Schreiner</name></region><name sortKey="Jalili, A" sort="Jalili, A" uniqKey="Jalili A" first="A" last="Jalili">A. Jalili</name><name sortKey="Rieger, A" sort="Rieger, A" uniqKey="Rieger A" first="A" last="Rieger">A. Rieger</name><name sortKey="Stingl, G" sort="Stingl, G" uniqKey="Stingl G" first="G" last="Stingl">G. Stingl</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:6B45A1E5BBC905C5EEFC70C2A1B9A59154C18108
|texte= P4.049 Lopinavir/Ritonavir in Combination with Tenofovir/Emtricitabine as Post Exposure Prophylaxis (PEP) to HIV - an Effective and Well Tolerated Regimen
}}
| This area was generated with Dilib version V0.6.31. |  |